The study encompassed commonly mutated genes in lung adenocarcinoma, including EGFR, KRAS, ALK, MET, BRAF, HER2, Tumor Protein 53 (TP53), phosphoinositide 3-kinase (PIK3), and avian Erythroblastosis ...

Beyond those two therapies, Nuvalent is currently enrolling patients in a Phase 1a/1b study (HEROEX-1) to assess NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2 ...

A new review was published in Oncotarget's Volume 16 on January 20, 2025, titled "Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms." Researchers ...

Most often, an accumulation of mutations in both oncogenes and tumor-suppressor genes is responsible for the development of cancer. Oncogenes arise when normal genes present in the body ...

Datroway is approved for HR-positive, HER2-negative breast cancer after prior endocrine and chemotherapy treatments. TROPION-Breast01 trial showed Datroway improved progression-free survival and ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer. The FDA has approved ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic breast cancer who had progressed on multiple ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...

Further as of the most recent follow up, the data show a strong trend in favor of OST-HER2-treated patients in overall survival (‘OS’, remaining alive) at the 1-year and 2-year interim ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...